These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15377484)

  • 1. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
    Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract]   [Full Text] [Related]  

  • 4. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
    Hong FS; Mitchell CA; Zantomio D
    Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
    [No Abstract]   [Full Text] [Related]  

  • 6. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events after imatinib mesylate therapy.
    Burton C; Azzi A; Kerridge I
    N Engl J Med; 2002 Feb; 346(9):712-3. PubMed ID: 11873781
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
    Ianotto JC; Tempescul A; Amet Y; Grall P; Dalbies F; Eveillard JR; Guillerm G; Berthou C
    Am J Hematol; 2012 Apr; 87(4):437-9. PubMed ID: 22287505
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 11. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 13. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
    Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 17. Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate.
    Basu S; Das T; Biswas G
    Ocul Immunol Inflamm; 2010 Jan; 18(1):64-5. PubMed ID: 20128654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of imatinib in the treatment of acute lymphoid leukemias].
    Poros A; Lovas N
    Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
    Wong M; Sade S; Gilbert M; Klieb HB
    Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adverse effects of imatinib mesylate].
    Isshiki I
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.